Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1/2 1Phase 1 1

Status

Completed 2Withdrawn 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 102Breast Neoplasms 81Neoplasms 72Neoplasm Metastasis 63Melanoma 63Leukemia, Myeloid, Acute 58Ovarian Neoplasms 54Lymphoma, Non-Hodgkin 52Prostatic Neoplasms 50Colorectal Neoplasms 50Multiple Myeloma 49Glioblastoma 48Pancreatic Neoplasms 47Lung Neoplasms 45Recurrence 41Carcinoma, Renal Cell 40Squamous Cell Carcinoma of Head and Neck 37Leukemia, Lymphocytic, Chronic, B-Cell 37Triple Negative Breast Neoplasms 35Myelodysplastic Syndromes 30Lymphoma, Large B-Cell, Diffuse 28Glioma 28Stomach Neoplasms 27Precursor Cell Lymphoblastic Leukemia-Lymphoma 27Lymphoma, B-Cell 27Brain Neoplasms 27Lymphoma, Follicular 26Endometrial Neoplasms 26Lymphoma 25Carcinoma, Hepatocellular 24

Interventions

Taxes 1Metformin 1Gemcitabine 1Albumin-Bound Paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Active not recruiting × Pancreatic Adenocarcinoma × Clear all
NCT02336087 2026-02-04

Gemcitabine Hydrochloride, Paclitaxel Albumin-Stabilized Nanoparticle Formulation, Metformin Hydrochloride, and a Standardized Dietary Supplement in Treating Patients With Pancreatic Cancer That Cannot be Removed by Surgery

City of Hope Medical Center

Phase 1 Active not recruiting
21 enrolled
Gastrointestinal

Pancreatic Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡